Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma

Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma

Abstract Natural killer/T-cell lymphoma (NKTCL) is a rare subtype of non-Hodgkin lymphoma that is associated with a poor outcome. Currently, the treatment needs of NKTCL remain unmet, and efforts to further improve treatment are urgently needed. Herein, seven patients with NKTCL who failed to respon...

Full description

Bibliographic Details
Main Authors: Xin Li, Yasong Cheng, Mingzhi Zhang, Jiaqin Yan, Ling Li, Xiaorui Fu, Xudong Zhang, Yu Chang, Zhenchang Sun, Hui Yu, Lei Zhang, Xinhua Wang, Jingjing Wu, Zhaoming Li, Feifei Nan, Li Tian, Wencai Li, Ken H. Young
Format: Article
Language:English
Published: BMC 2018-01-01
Series:Journal of Hematology & Oncology
Subjects:
NK/T-cell lymphoma
PD-1 blockade
Pembrolizumab
Online Access:http://link.springer.com/article/10.1186/s13045-018-0559-7

Internet

http://link.springer.com/article/10.1186/s13045-018-0559-7

Similar Items